Effects of omega-3 polyunsaturated fatty acids on heart function and oxidative stress biomarkers in pediatric patients with dilated cardiomyopathy

International Cardiovascular Research Journal

Volumn 7, Issue 1, 2013, Pages 8-14

  Firuzi, Omidreza ^a   Shakibazad, Nader ^b   Amoozgar, Hamid ^b,c   Borzoee, Mohammad ^b   Abtahi, Saeed ^b   Ajami, Gholamhossein ^b   Ardi, Pegah ^a   Miri, Ramin ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dilated cardiomyopathy; Omega 3; Polyunsaturated fatty acid

Indexed keywords

CATALASE; COD LIVER OIL; DOCOSAHEXAENOIC ACID; GLUTATHIONE PEROXIDASE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PROSTAGLANDIN F2 ALPHA; RETINOL; VITAMIN D;

ANTIOXIDANT ACTIVITY; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFANT; M MODE ECHOCARDIOGRAPHY; MALE; MITRAL VALVE; OXIDATIVE STRESS; PRESCHOOL CHILD; TISSUE DOPPLER IMAGING; TRICUSPID VALVE; ULTRASOUND SCANNER;

EID: 84880976001     PISSN: 22519130     EISSN: 22519149     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45(7):969-81.
2. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375(9716):752-62.
3. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45(7):969-81.
4. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-76.
5. Chen SC. Echocardiography of dilated cardiomyopathy in children. Echocardiography. 1991;8(2):207-17.
6. McMahon CJ, Nagueh SF, Eapen RS, Dreyer WJ, Finkelshtyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90(8):908-15.
7. Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr. 2009;10(8):iii15-iii21.
8. Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000;86(2):152-7.
9. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3(3):221-9.
10. Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol. 2008;101(10A):75D-86D.
11. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003;57(8):904-8.
12. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18(25):3871-88.
13. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002;166(5):608-15.
14. Mozaffarian D. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Clin Nutr. 2008;87(6):1991S-6S.
15. Mozaffarian D, Wu JH. n-3 fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012;142(3):614S-25S.
16. Poudyal H, Panchal SK, Diwan V, Brown L. Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res. 2011;50(4):372-87.
17. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res. 2007;76(2):303-10.
18. Duda MK, O'Shea KM, Stanley WC. omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33-41.
19. Duda MK, O'Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res. 2009;81(2):319-27.
20. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(7):870-9.
21. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a doubleblind, placebo-controlled, 3-arm study. Am Heart J. 2011;161(5):915. e1-9.
22. Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, et al. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils. Heart Rhythm. 2011;8(5):643-9.
23. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6.
24. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70(1):158-69.
25. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239(1):70-6.
26. Miri R, Saadati H, Ardi P, Firuzi O. Alterations in oxidative stress biomarkers associated with mild hyperlipidemia and smoking. Food Chem Toxicol. 2012;50(3-4):920-6.
27. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7):585-94.
28. Olgar S, Ertugrul T, Nisli K, Omeroglu RE, Dindar A, Aydogan U. Fish oil supplementation improves left ventricular function in children with idiopathic dilated cardiomyopathy. Congest Heart Fail. 2007;13(6):308-12.
29. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and metaanalysis. JAMA. 2012;308(10):1024-33.
30. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35(7):772-81.
31. Nalsen C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, et al. Dietary (n-3) fatty acids reduce plasma F2isoprostanes but not prostaglandin F2alpha in healthy humans. J Nutr. 2006;136(5):1222-8.
32. Kimura Y, Sato M, Kurotani K, Nanri A, Kawai K, Kasai H, et al. PUFAs in serum cholesterol ester and oxidative DNA damage in Japanese men and women. Am J Clin Nutr. 2012;95(5):1209-14.
33. Carrepeiro MM, Rogero MM, Bertolami MC, Botelho PB, Castro N, Castro IA. Effect of n-3 fatty acids and statins on oxidative stress in statin-treated hypercholestorelemic and normocholesterolemic women. Atherosclerosis. 2011;217(1):171-8.
34. Egert S, Lindenmeier M, Harnack K, Krome K, Erbersdobler HF, Wahrburg U, et al. Margarines Fortified with-Linolenic Acid, Eicosapentaenoic Acid, or Docosahexaenoic Acid Alter the Fatty Acid Composition of Erythrocytes but Do Not Affect the Antioxidant Status of Healthy Adults. J Nutr. 2012;142(9):1638-44.
35. Filaire E, Massart A, Portier H, Rouveix M, Rosado F, Bage AS, et al. Effect of 6 Weeks of n-3 fatty-acid supplementation on oxidative stress in Judo athletes. Int J Sport Nutr Exerc Metab. 2010;20(6):496-506.
36. Petersson H, Risérus U, McMonagle J, Gulseth HL, Tierney AC, Morange S, et al. Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study. Br J Nutr. 2010;104(9):1357-62.
37. Signori C, DuBrock C, Richie JP, Prokopczyk B, Demers LM, Hamilton C, et al. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. Eur J Clin Nutr. 2012;66(8):878-84.
38. Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaddous A, Bouchenak M. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia. J Ren Nutr. 2010;20(5):321-8.